Appointment of Joint Corporate Broker

RNS Number : 9700H
Uniphar PLC
09 December 2020
 

Appointment of Joint Corporate Broker

 

 

 

Dublin, London | 9 December 2020: Uniphar plc ("Uniphar" or the "Group") today announces that it has appointed Stifel Nicolaus Europe Limited as its joint corporate broker, alongside Davy and RBC Capital Markets, with immediate effect.

 

--Ends--

 

For further details contact:

 

Uniphar

+353 (0) 1 428 7777

 

 

Brian O'Shaughnessy

 

Group Director of Corporate Development

investor.relations@Uniphar.ie

 

 

Davy

+353 (0) 1 679 6363

(Joint Corporate Broker, Nominated Adviser and Euronext

Growth Adviser)

 

 

 

Fergal Meegan

 

Barry Murphy

 

Orla Cowzer

 

 

 

RBC Capital Markets (Joint Corporate Broker)

+44 (0) 20 7653 4000

 

 

Darrell Uden

 

Jonathan Hardy

 

Jamil Miah

 

 

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

Matt Blawat

 

Ben Madison

 

Francis North

 

 

 

Q4 PR

+353 (0) 1 475 1444 or

(Public Relations Adviser to Uniphar)

+353 87 235 6461

 

 

Iarla Mongey

 

 

 

 

About Uniphar plc  

 

Headquartered in Dublin, Ireland, Uniphar plc is an international diversified healthcare services business, servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail.

 

The Group has strong established relationships with 7 of the top 10 pharma companies and 6 of the top 10 medical device companies. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US, delivering unlicensed and specialty medicine on a global basis.

 

The Group's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

 

Commercial & Clinical

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux, and the Nordics, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

 

Product Access

In Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

 

Supply Chain & Retail

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEASAPEFNEFFA
UK 100

Latest directors dealings